Appili Deepens Non-Dilutive Funding Base as Infectious Disease Pipeline Advances

Appili Therapeutics Inc Class A ( (TSE:APLI) ) has shared an update.

Appili reported third-quarter fiscal 2026 results that underscore its strategy of leveraging non-dilutive government funding and partnerships to advance its infectious disease and biodefense pipeline. The company has secured more than US$75 million in cumulative government support and has a further US$82 million in proposals under review, supporting activities from manufacturing to clinical trial preparation while limiting shareholder dilution.

Pipeline progress featured the ATI-1801 topical antiparasitic program for cutaneous leishmaniasis, which now has a clearly defined U.S. regulatory path toward a potential NDA, with efforts underway to secure additional global health funding. Commercially, LIKMEZ, the first FDA-approved liquid oral formulation of metronidazole, is showing steady U.S. sales growth and is protected by patents extending to 2039, offering a growing royalty and milestone revenue stream.

In biodefense, ATI-1701, a tularemia vaccine candidate, reached a key milestone with successful GMP manufacturing of drug substance and product, positioning it for Phase 1 clinical use. The most significant new funding event was a contract of up to US$40 million from NIAID to advance VXV-01, a dual-antigen vaccine targeting multidrug-resistant Candida, where Appili leads development and holds an exclusive option to acquire global rights, potentially cementing its role in the emerging fungal vaccine field.

The most recent analyst rating on (TSE:APLI) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Appili Therapeutics Inc Class A stock, see the TSE:APLI Stock Forecast page.

Spark’s Take on TSE:APLI Stock

According to Spark, TipRanks’ AI Analyst, TSE:APLI is a Neutral.

The score is primarily constrained by weak financial performance—persistent losses, negative equity, and reliance on external funding. Technical signals are mixed-to-neutral and do not materially offset the financial risk, while valuation is also challenged by negative earnings and no dividend support.

To see Spark’s full report on TSE:APLI stock, click here.

More about Appili Therapeutics Inc Class A

Appili Therapeutics Inc. is a Halifax-based biopharmaceutical company focused on developing drugs for infectious diseases and medical countermeasures. Its portfolio spans topical antiparasitic therapies, oral antibiotic formulations, vaccines for high-consequence pathogens, and novel fungal vaccines, targeting both commercial markets and government-backed biodefense and global health initiatives.

Average Trading Volume: 55,978

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$3.03M

See more insights into APLI stock on TipRanks’ Stock Analysis page.